Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fifteen research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eleven have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $47.40.
TYRA has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Thursday, October 15th. Piper Sandler reiterated an “overweight” rating and set a $56.00 price target on shares of Tyra Biosciences in a research report on Tuesday, September 8th. HC Wainwright decreased their price target on shares of Tyra Biosciences from $29.00 to $27.00 and set a “buy” rating for the company in a research note on Wednesday, November 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Tyra Biosciences in a report on Thursday, September 10th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $42.00 price objective on shares of Tyra Biosciences in a research report on Wednesday, August 5th.
Get Our Latest Research Report on TYRA
Tyra Biosciences Stock Performance
Shares of TYRA stock opened at $19.74 on Friday. The business has a 50-day moving average of $21.57 and a 200 day moving average of $29.32. Tyra Biosciences has a 1-year low of $14.84 and a 1-year high of $40.65.
Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.07). As a group, equities analysts anticipate that Tyra Biosciences will post -2.77 EPS for the current year.
Hedge Funds Weigh In On Tyra Biosciences
Institutional investors have recently added to or reduced their stakes in the company. Jupiter Topco LLC purchased a new stake in shares of Tyra Biosciences in the 2nd quarter worth about $139,161,000. Janus Henderson Group PLC lifted its position in Tyra Biosciences by 32.5% during the 1st quarter. Janus Henderson Group PLC now owns 3,890,589 shares of the company’s stock valued at $148,867,000 after acquiring an additional 955,147 shares during the period. BlackRock Inc. bought a new stake in Tyra Biosciences during the second quarter worth about $96,841,000. 5AM Venture Management LLC bought a new stake in Tyra Biosciences during the second quarter worth about $32,875,778. Finally, Jennison Associates LLC bought a new stake in Tyra Biosciences during the first quarter worth about $24,222,000. Institutional investors own 84.14% of the company’s stock.
About Tyra Biosciences
Tyra Biosciences, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges. The company’s pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers.
Featured Stories
- Five stocks we like better than Tyra Biosciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
